Literature DB >> 17009391

Probiotics and prebiotics in chronic inflammatory bowel diseases.

Julia B Ewaschuk1, Levinus A Dieleman.   

Abstract

The prokaryotic and eukaryotic cells of the colon exist in a highly complex, but harmonious relationship. Disturbances in this remarkable symbiosis can result in the development of inflammatory bowel diseases (IBD). Although the etiology of IBD is not entirely understood, it is known that the chronic inflammation of Crohn's disease, ulcerative colitis and chronic pouchitis are a result of an overly aggressive immune response to the commensal intestinal flora in genetically susceptible hosts. Recent studies have enhanced our ability to understand the interaction between the host and its intestinal microflora and the role the microflora plays in maintaining intestinal homeostasis. As we begin to understand the benefits conferred to the intestine by the microflora, the notion of modifying the composition of the bacterial load to improve human health has arisen. A significant body of research now exists investigating the role of probiotics and prebiotics in ameliorating chronic intestinal inflammation. This article will begin with an overview of the role of the commensal microflora in maintaining mucosal immune homeostasis, and how a dysregulated immune response to the intestinal microflora results in IBD. This will be followed by a summary of the use of probiotics and prebiotics in experimental and human IBD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17009391      PMCID: PMC4124400          DOI: 10.3748/wjg.v12.i37.5941

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  117 in total

1.  Reduced ratio of protective versus proinflammatory cytokine responses to commensal bacteria in HLA-B27 transgenic rats.

Authors:  L A Dieleman; F Hoentjen; B-F Qian; D Sprengers; E Tjwa; M F Torres; C D Torrice; R B Sartor; S L Tonkonogy
Journal:  Clin Exp Immunol       Date:  2004-04       Impact factor: 4.330

2.  Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.

Authors:  T Mimura; F Rizzello; U Helwig; G Poggioli; S Schreiber; I C Talbot; R J Nicholls; P Gionchetti; M Campieri; M A Kamm
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

3.  Effects of feeding a probiotic preparation (SIM) containing inulin on the severity of colitis and on the composition of the intestinal microflora in HLA-B27 transgenic rats.

Authors:  M Schultz; K Munro; G W Tannock; I Melchner; C Göttl; H Schwietz; J Schölmerich; H C Rath
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

4.  DNA from probiotic bacteria modulates murine and human epithelial and immune function.

Authors:  Humberto Jijon; Jody Backer; Hugo Diaz; Helen Yeung; David Thiel; Conor McKaigney; Claudio De Simone; Karen Madsen
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

5.  Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport.

Authors:  S Ménard; C Candalh; J C Bambou; K Terpend; N Cerf-Bensussan; M Heyman
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

6.  Effects of probiotic on intestinal mucosa of patients with ulcerative colitis.

Authors:  Hai-Hong Cui; Cun-Long Chen; Ji-De Wang; Yu-Jie Yang; Yong Cun; Jin-Bao Wu; Yu-Hu Liu; Han-Lei Dan; Yan-Ting Jian; Xue-Qing Chen
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

7.  Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis.

Authors:  Daniel Rachmilewitz; Kyoko Katakura; Fanny Karmeli; Tomoko Hayashi; Constantin Reinus; Bernard Rudensky; Shizuo Akira; Kiyoshi Takeda; Jongdae Lee; Kenji Takabayashi; Eyal Raz
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

8.  Germinated barley foodstuff prolongs remission in patients with ulcerative colitis.

Authors:  Hiroyuki Hanai; Osamu Kanauchi; Keiichi Mitsuyama; Akira Andoh; Ken Takeuchi; Iida Takayuki; Yoshio Araki; Yoshihide Fujiyama; Atsushi Toyonaga; Michio Sata; Atsushi Kojima; Masanobu Fukuda; Tadao Bamba
Journal:  Int J Mol Med       Date:  2004-05       Impact factor: 4.101

Review 9.  Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics.

Authors:  R Balfour Sartor
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

10.  Lactobacillus GG in inducing and maintaining remission of Crohn's disease.

Authors:  Michael Schultz; Antje Timmer; Hans H Herfarth; R Balfour Sartor; Jon A Vanderhoof; Heiko C Rath
Journal:  BMC Gastroenterol       Date:  2004-03-15       Impact factor: 3.067

View more
  35 in total

1.  Anti-inflammatory and immunomodulatory efficacy of indigenous probiotic Lactobacillus plantarum Lp91 in colitis mouse model.

Authors:  Raj Kumar Duary; Mache Amit Bhausaheb; Virender Kumar Batish; Sunita Grover
Journal:  Mol Biol Rep       Date:  2011-09-23       Impact factor: 2.316

2.  Lactobacillus rhamnosus GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injury.

Authors:  Yuhua Wang; Yanlong Liu; Anju Sidhu; Zhenhua Ma; Craig McClain; Wenke Feng
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-04-26       Impact factor: 4.052

Review 3.  Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy.

Authors:  M-I Torres; A Rios
Journal:  World J Gastroenterol       Date:  2008-04-07       Impact factor: 5.742

4.  Inhibition of the NF-kappaB pathway in human intestinal epithelial cells by commensal Streptococcus salivarius.

Authors:  Ghalia Kaci; Omar Lakhdari; Joël Doré; S Dusko Ehrlich; Pierre Renault; Hervé M Blottière; Christine Delorme
Journal:  Appl Environ Microbiol       Date:  2011-05-20       Impact factor: 4.792

5.  A common antimicrobial additive increases colonic inflammation and colitis-associated colon tumorigenesis in mice.

Authors:  Haixia Yang; Weicang Wang; Kymberleigh A Romano; Min Gu; Katherine Z Sanidad; Daeyoung Kim; Jun Yang; Birgitta Schmidt; Dipak Panigrahy; Ruisong Pei; Derek A Martin; E Ilker Ozay; Yuxin Wang; Mingyue Song; Bradley W Bolling; Hang Xiao; Lisa M Minter; Guang-Yu Yang; Zhenhua Liu; Federico E Rey; Guodong Zhang
Journal:  Sci Transl Med       Date:  2018-05-30       Impact factor: 17.956

Review 6.  Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years?

Authors:  Georgina L Hold; Megan Smith; Charlie Grange; Euan Robert Watt; Emad M El-Omar; Indrani Mukhopadhya
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

Review 7.  Diet therapy for inflammatory bowel diseases: The established and the new.

Authors:  Franziska Durchschein; Wolfgang Petritsch; Heinz F Hammer
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

8.  Screening of Probiotic Lactic Acid Bacteria Isolated from Fermented Pak-Sian for Use as a Starter Culture.

Authors:  Supaporn Pumriw; Vijitra Luang-In; Wannee Samappito
Journal:  Curr Microbiol       Date:  2021-05-21       Impact factor: 2.188

Review 9.  Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.

Authors:  Diego Currò; Gianluca Ianiro; Silvia Pecere; Stefano Bibbò; Giovanni Cammarota
Journal:  Br J Pharmacol       Date:  2016-10-25       Impact factor: 8.739

10.  Bacterial translocation to mesenteric lymph nodes increases in chronic portal hypertensive rats.

Authors:  Miguel-Angel Llamas; María-Angeles Aller; Domingo Marquina; María-Paz Nava; Jaime Arias
Journal:  Dig Dis Sci       Date:  2009-10-16       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.